{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:00:15Z","timestamp":1790283615110,"version":"4.1.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Modulating the regimen of biologics is of increasing interest in patients with psoriasis. This includes dose reduction (de-escalation) and dose augmentation (escalation). De-escalation strategies include reducing the single therapeutic dose, the mg kg\u22121 ratio or the number of injections, and dose spacing (D-S), extending the interval between administrations. Real-life data regarding dose de-escalation are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To retrospectively analyse the effectiveness and drug survival of D-S of secukinumab and brodalumab in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a cohort study with retrospective analysis of the general characteristics of patients with psoriasis undergoing therapeutic biologic D-S with secukinumab or brodalumab and the effectiveness of D-S.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty patients underwent dose modulation by D-S with the interval increased by 50% of the approved range. Overall, 31 (39%) were treated with secukinumab and 49 (61%) with brodalumab. After a mean of 35\u2005months, the population underwent D-S. At D-S, the mean Psoriasis Area and Severity Index (PASI) was 0.1, ranging from 0.7 to 0.1 in the following year. PASI 100 (100% improvement) was achieved by 91% at the date of D-S and remained stable over the following year. Similar trends were seen for PASI 90 and absolute PASI \u2264 1, with 99% and 100% of patients, respectively, achieving these goals at the time of D-S. These levels were maintained at 12\u2005months after D-S. The 12-month drug survival of the D-S regimen was 66%, with one-quarter of patients (20 of 80) returning to the standard dosage. PASI 100 was regained in two-thirds of these cases. Secukinumab showed a drug survival after D-S of 78%, compared with 59% for brodalumab. No differences in mean and relative PASI scores at any timepoint after D-S were found between the two treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Therapeutic modulation of interleukin-17 inhibitors in patients with psoriasis and controlled disease seems an effective therapeutic strategy that maintains efficacy for up to 1\u2005year in 40% of patients. No differences were observed between secukinumab and brodalumab during the D-S regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf250","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T20:01:22Z","timestamp":1749672082000},"page":"2172-2178","source":"Crossref","is-referenced-by-count":4,"title":["Dose modulation strategies in patients with psoriasis: real-world comparison between secukinumab and\u00a0brodalumab for up to 1\u2005year after dose spacing"],"prefix":"10.1093","volume":"50","author":[{"given":"Luca","family":"Mastorino","sequence":"first","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1915-9993","authenticated-orcid":false,"given":"Eleonora","family":"Bongiovanni","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Liao","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Pelucchi","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Leo","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"2025102707123883900_llaf250-B1","doi-asserted-by":"crossref","first-page":"adv00821","DOI":"10.2340\/actadv.v102.1982","article-title":"Risk of reactivation of latent tuberculosis in psoriasis patients on biologic therapies: a retrospective cohort from a tertiary care centre in Northern Italy","volume":"102","author":"Mastorino","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2025102707123883900_llaf250-B2","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2025102707123883900_llaf250-B3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jdv.19682","article-title":"Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5\u2005years","volume":"38","author":"Mastorino","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025102707123883900_llaf250-B4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","article-title":"Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: a retrospective, multinational, multicentre study","volume":"25","author":"Torres","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2025102707123883900_llaf250-B5","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/14712598.2023.2244872","article-title":"Reduced doses of biological therapies in psoriasis: a new potentially \u2018sustainable\u2019 frontier of psoriasis treatment","volume":"23","author":"Ribero","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2025102707123883900_llaf250-B6","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1111\/jdv.18908","article-title":"Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: a safe and effective practice?","volume":"37","author":"Mastorino","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025102707123883900_llaf250-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-017-0055-5","article-title":"bDMARD dose reduction in rheumatoid arthritis: a narrative review with systematic literature search","volume":"4","author":"Verhoef","year":"2017","journal-title":"Rheumatol Ther"},{"key":"2025102707123883900_llaf250-B8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40265-020-01448-z","article-title":"Dose tapering of biologics in patients with psoriasis: a scoping review","volume":"81","author":"Michielsens","year":"2021","journal-title":"Drugs"},{"key":"2025102707123883900_llaf250-B9","doi-asserted-by":"crossref","first-page":"e713","DOI":"10.1111\/jdv.18182","article-title":"Is risankizumab as needed administration a good option for patients with plaque psoriasis?","volume":"36","author":"Gisondi","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025102707123883900_llaf250-B10","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Sch\u00e4kel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025102707123883900_llaf250-B11","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/exd.14731","article-title":"Superresponders\u2019 at biologic treatment for psoriasis: a comparative study among IL17 and IL23 inhibitors","volume":"32","author":"Mastorino","year":"2023","journal-title":"Exp Dermatol"},{"key":"2025102707123883900_llaf250-B12","first-page":"34","article-title":"Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment","volume":"22","author":"Mastorino","year":"2024","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"2025102707123883900_llaf250-B13","doi-asserted-by":"crossref","first-page":"1369805","DOI":"10.3389\/fphar.2024.1369805","article-title":"Dose reduction of biologics in patients with plaque psoriasis: a review","volume":"15","author":"van Riel","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025102707123883900_llaf250-B14","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.18143","article-title":"Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025102707123883900_llaf250-B15","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"2025102707123883900_llaf250-B16","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/jdv.18827","article-title":"Blocking interleukin-17 in psoriasis: real-world experience from the PsoPlus cohort","volume":"37","author":"Schots","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025102707123883900_llaf250-B17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/ijd.16915","article-title":"Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting","volume":"63","author":"Daud\u00e9n","year":"2024","journal-title":"Int J Dermatol"},{"key":"2025102707123883900_llaf250-B18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1186\/s13063-021-05681-z","article-title":"Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study \u2013 the BeNeBio study","volume":"22","author":"van der Schoot","year":"2021","journal-title":"Trials"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf250\/63472727\/llaf250.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/11\/2172\/63472727\/llaf250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/11\/2172\/63472727\/llaf250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:12:44Z","timestamp":1761563564000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/11\/2172\/8160591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":18,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,12]]},"published-print":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf250","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,12]]}}}